Login
Register
Submit a Paper
Propose a Special lssue
Open Access
HOW I DO IT
How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer
Division of Urology, McMaster Institute of Urology, Hamilton, Ontario, Canada
Address correspondence to Dr. Bobby Shayegan, McMaster
Institute of Urology, 50 Charlton Avenue East, Room G339A,
Hamilton, ON L8N 4A6 Canada
Canadian Journal of Urology 2016, 23(4), 8388-8394.
Download PDFAbstract
Abiraterone acetate (AA) is a selective irreversible inhibitor of CYP 17, a key enzyme in androgen biosynthesis. The efficacy and safety of AA in improving survival and quality of life in metastatic castration resistant prostate cancer (mCRPC) has been demonstrated in two landmark clinical trials (COU-AA-301 and COU-AA-302). This article will review the rationale, pharmacology, clinical indications and contraindications, administration, and adverse effects of AA administration in mCRPC.Keywords
abiraterone acetate, abiraterone, Zytiga, metastatic castrate resistant prostate cancer, mCRPC, CYP17, prostate cancer
Cite This Article
APA Style
Wang, Y., Dason, S., Shayegan, B. (2016). How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer. Canadian Journal of Urology, 23(4), 8388–8394.
Vancouver Style
Wang Y, Dason S, Shayegan B. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer. Can J Urology. 2016;23(4):8388–8394.
IEEE Style
Y. Wang, S. Dason, and B. Shayegan, “How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer,” Can. J. Urology, vol. 23, no. 4, pp. 8388–8394, 2016.
Copyright © 2016 The Canadian Journal of Urology.
Downloads
Citation Tools
